Clinical Trial Update: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate AZD6738 in combination with acalabrutinib in relapsed or refractory chronic lymphocytic leukemia; the trial is active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• AZD6738 (ceralasertib)
• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING